DK2089032T3 - Farmaceutisk præparat der har antipsykotisk, antidepressiv eller antiepileptisk aktivitet med reducerede bivirkninger - Google Patents
Farmaceutisk præparat der har antipsykotisk, antidepressiv eller antiepileptisk aktivitet med reducerede bivirkningerInfo
- Publication number
- DK2089032T3 DK2089032T3 DK07766499.3T DK07766499T DK2089032T3 DK 2089032 T3 DK2089032 T3 DK 2089032T3 DK 07766499 T DK07766499 T DK 07766499T DK 2089032 T3 DK2089032 T3 DK 2089032T3
- Authority
- DK
- Denmark
- Prior art keywords
- antidepressant
- antipsychotic
- side effects
- pharmaceutical preparation
- reduced side
- Prior art date
Links
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 2
- 239000000935 antidepressant agent Substances 0.000 title abstract 2
- 230000001430 anti-depressive effect Effects 0.000 title 1
- 230000003556 anti-epileptic effect Effects 0.000 title 1
- 229940005513 antidepressants Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85617706P | 2006-11-02 | 2006-11-02 | |
| US11/687,954 US20080108602A1 (en) | 2006-11-02 | 2007-03-19 | Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication |
| PCT/HU2007/000067 WO2008053257A1 (en) | 2006-11-02 | 2007-07-23 | A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2089032T3 true DK2089032T3 (da) | 2011-03-14 |
Family
ID=38595981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07766499.3T DK2089032T3 (da) | 2006-11-02 | 2007-07-23 | Farmaceutisk præparat der har antipsykotisk, antidepressiv eller antiepileptisk aktivitet med reducerede bivirkninger |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20080108602A1 (da) |
| EP (1) | EP2089032B1 (da) |
| JP (1) | JP2010509200A (da) |
| KR (1) | KR20090077973A (da) |
| AT (1) | ATE491452T1 (da) |
| AU (1) | AU2007315932A1 (da) |
| BR (1) | BRPI0717868A2 (da) |
| CA (1) | CA2668384A1 (da) |
| DE (1) | DE602007011316D1 (da) |
| DK (1) | DK2089032T3 (da) |
| HR (1) | HRP20110139T1 (da) |
| IL (1) | IL198294A (da) |
| MX (1) | MX2009004579A (da) |
| NO (1) | NO20092024L (da) |
| PL (1) | PL2089032T3 (da) |
| PT (1) | PT2089032E (da) |
| RU (1) | RU2440116C2 (da) |
| SI (1) | SI2089032T1 (da) |
| WO (1) | WO2008053257A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009074835A1 (en) * | 2007-12-10 | 2009-06-18 | N-Gene Research Laboratories Inc. | Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity |
| HUP1100445A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
| HUP1100444A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
| JP6807094B2 (ja) * | 2016-04-29 | 2021-01-06 | 国立大学法人秋田大学 | クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法 |
| WO2018098497A1 (en) | 2016-11-28 | 2018-05-31 | Lb Pharmaceuticals Inc. | Psychotropic agents and uses thereof |
| WO2020006367A1 (en) * | 2018-06-29 | 2020-01-02 | Tufts Medical Center, Inc. | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions |
| HUP1800298A1 (hu) | 2018-08-30 | 2020-05-28 | N Gene Res Laboratories Inc | Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére |
| WO2025046526A1 (ko) * | 2023-09-01 | 2025-03-06 | 환인제약 주식회사 | 설트랄린 또는 이의 염을 포함하는 약학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187220A (en) * | 1977-08-30 | 1980-02-05 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| HU9502843D0 (en) * | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
| US6458371B1 (en) * | 1995-12-22 | 2002-10-01 | Medgene, Limited | Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin |
| US6884424B2 (en) * | 1995-12-22 | 2005-04-26 | N-Gene Research Laboratories Inc. | Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight |
| HUP9701080A3 (en) * | 1997-06-23 | 1999-05-28 | Gene Res Lab Inc New York N | Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative |
| HU9701081D0 (en) * | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
| IL159412A0 (en) * | 2001-07-17 | 2004-06-01 | N Gene Res Lab Inc | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| HUP0401177A2 (en) * | 2004-06-14 | 2007-09-28 | N Gene Res Lab Inc | Pharmaceutical composition for increasing the mitochondrial genesis |
-
2007
- 2007-03-19 US US11/687,954 patent/US20080108602A1/en not_active Abandoned
- 2007-07-23 EP EP07766499A patent/EP2089032B1/en active Active
- 2007-07-23 KR KR1020097011078A patent/KR20090077973A/ko not_active Ceased
- 2007-07-23 BR BRPI0717868-9A2A patent/BRPI0717868A2/pt not_active IP Right Cessation
- 2007-07-23 WO PCT/HU2007/000067 patent/WO2008053257A1/en not_active Ceased
- 2007-07-23 AU AU2007315932A patent/AU2007315932A1/en not_active Abandoned
- 2007-07-23 PT PT07766499T patent/PT2089032E/pt unknown
- 2007-07-23 PL PL07766499T patent/PL2089032T3/pl unknown
- 2007-07-23 CA CA002668384A patent/CA2668384A1/en not_active Abandoned
- 2007-07-23 DK DK07766499.3T patent/DK2089032T3/da active
- 2007-07-23 AT AT07766499T patent/ATE491452T1/de active
- 2007-07-23 JP JP2009535138A patent/JP2010509200A/ja active Pending
- 2007-07-23 HR HR20110139T patent/HRP20110139T1/hr unknown
- 2007-07-23 DE DE602007011316T patent/DE602007011316D1/de active Active
- 2007-07-23 SI SI200730539T patent/SI2089032T1/sl unknown
- 2007-07-23 MX MX2009004579A patent/MX2009004579A/es active IP Right Grant
- 2007-07-23 RU RU2009120115/15A patent/RU2440116C2/ru not_active IP Right Cessation
-
2009
- 2009-04-22 IL IL198294A patent/IL198294A/en not_active IP Right Cessation
- 2009-05-25 NO NO20092024A patent/NO20092024L/no not_active Application Discontinuation
-
2010
- 2010-08-17 US US12/858,299 patent/US20100311719A1/en not_active Abandoned
-
2015
- 2015-06-23 US US14/748,150 patent/US20150366852A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL2089032T3 (pl) | 2011-05-31 |
| US20080108602A1 (en) | 2008-05-08 |
| US20150366852A1 (en) | 2015-12-24 |
| HK1131736A1 (en) | 2010-02-05 |
| IL198294A (en) | 2011-09-27 |
| CA2668384A1 (en) | 2008-05-08 |
| RU2009120115A (ru) | 2010-12-10 |
| WO2008053257A1 (en) | 2008-05-08 |
| RU2440116C2 (ru) | 2012-01-20 |
| MX2009004579A (es) | 2009-06-05 |
| EP2089032A1 (en) | 2009-08-19 |
| IL198294A0 (en) | 2010-02-17 |
| AU2007315932A1 (en) | 2008-05-08 |
| PT2089032E (pt) | 2011-03-23 |
| HRP20110139T1 (hr) | 2011-04-30 |
| SI2089032T1 (sl) | 2011-04-29 |
| US20100311719A1 (en) | 2010-12-09 |
| BRPI0717868A2 (pt) | 2013-10-29 |
| NO20092024L (no) | 2009-06-02 |
| KR20090077973A (ko) | 2009-07-16 |
| JP2010509200A (ja) | 2010-03-25 |
| EP2089032B1 (en) | 2010-12-15 |
| ATE491452T1 (de) | 2011-01-15 |
| DE602007011316D1 (de) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2089032T3 (da) | Farmaceutisk præparat der har antipsykotisk, antidepressiv eller antiepileptisk aktivitet med reducerede bivirkninger | |
| EP3251674A3 (en) | Antiviral azasugar-containing nucleosides | |
| EA201270800A1 (ru) | С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| BRPI0910758A2 (pt) | composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| CY1120435T1 (el) | Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου | |
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| NO20065271L (no) | Sammensetninger innbefattende alfa-2-delta ligander | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| WO2012100043A3 (en) | Controlled release oral pharmaceutical dosage forms comprising mgbg | |
| ZA201007391B (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood | |
| DE602007010819D1 (de) | Verringerung von übergewicht oder fettsucht | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| WO2012142575A3 (en) | Monomeric trioxane amide sulfur compounds | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| MX346316B (es) | Formulacion farmaceutica o nutraceutica. | |
| WO2011058336A3 (en) | Tablet comprising gum arabic | |
| TW200800977A (en) | A new salt | |
| MX2012007393A (es) | Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam. | |
| WO2011035343A3 (en) | Phentermine liquid dosage form | |
| AU2016219606A1 (en) | Pharmaceutical composition for treating or preventing burn injuries | |
| WO2012091425A3 (ko) | 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물 |